EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Encapsulation of Dexamethasone into mRNA–Lipid Nanoparticles Is a Promising Approach for the Development of Liver-Targeted Anti-Inflammatory Therapies

Ignacio Rivero Berti, Rocío Celeste Gambaro, María José Limeres iD, Cristián Huck-Iriart iD, Malin Svensson, Silvia Fraude-El Ghazi, Leah Pretsch, Shutian Si, Ingo Lieberwirth, Katharina Landfester, Maximiliano Luis Cacicedo iD, Germán Abel Islan iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252011254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ignacio Rivero Berti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital, University Medical Center of the Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany. Hauptthemen laut MEDLINE: Dexamethasone, Nanoparticles, Anti-Inflammatory Agents, RNA, Messenger. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study was to develop two lipid nanoparticle (LNP) formulations capable of efficiently expressing a reporter mRNA while co-delivering the anti-inflammatory drug dexamethasone (DX) to reduce inflammatory side effects in protein replacement therapies. Two types of LNPs were developed, in which 25% of cholesterol was replaced by DX. These LNPs contained either 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as a helper lipid. The resulting LNPs exhibited high stability, homogeneity, and near-neutral Zeta potentials. SAXS experiments confirmed DX incorporation into the LNP core, with slow in vitro DX release observed over 48 h. The LNPs achieved high mRNA encapsulation efficiency (95–100%) and effectively transfected HepG2 cells, dendritic cells, and hPBMCs. While LNPs increased cytokine release (IL-1β, TNF-α, MCP-1), LNPs-DX significantly reduced cytokine levels, demonstrating enhanced anti-inflammatory properties while maintaining mRNA expression levels. In vivo biodistribution showed predominant liver localization post-intramuscular injection, regardless of the DSPC or DOPE composition. LNPs co-loaded with mRNA and DX are promising candidates for continuous protein replacement. Due to their ability to reduce treatment-related inflammation while maintaining significant mRNA expression levels, these LNPs are perfectly suited for the treatment of liver-related metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneNanoparticlesAnti-Inflammatory AgentsRNA, MessengerLiverPhosphatidylethanolaminesHumansAnimalsHep G2 CellsMicePhosphatidylcholinesTissue DistributionCytokinesLiposomes

Stichwörter der Autor:innen

anti-inflammatorycytokinesdendritic cellsdexamethasonehPBMCsin vivo biodistributionlipid nanoparticlesmRNA delivery

Substanzen

DexamethasoneAnti-Inflammatory AgentsRNA, MessengerPhosphatidylethanolaminesPhosphatidylcholinesLipid Nanoparticles1,2-distearoyllecithin1,2-dielaidoylphosphatidylethanolamineCytokinesLiposomes

Autor:innen und Institutionen

  • Children's Hospital, University Medical Center of the Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany.
  • CINDEFI-Centro de Investigación y Desarrollo en Fermentaciones Industriales, Laboratorio de Nanobiomateriales, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP)-Consejo Nacional de Investigaciones Ci…
  • ALBA Synchrotron Light Source, Carrer de la Llum 2-26, Cerdanyola del Vallès, 08290 Barcelona, Spain.
  • Max Planck Institute for Polymer Research, Department of Physical Chemistry of Polymers, Ackermannweg 10, 55128 Mainz, Germany.

ORCID-Profile: María José Limeres, Cristián Huck-Iriart, Maximiliano Luis Cacicedo, Germán Abel Islan, Stephan Gehring

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Rivero Berti, I., Gambaro, R. C., Limeres, M. J., Huck-Iriart, C., Svensson, M., Fraude-El Ghazi, S., Pretsch, L., Si, S., Lieberwirth, I., Landfester, K., Cacicedo, M. L., Islan, G. A., & Gehring, S. (2024). Encapsulation of Dexamethasone into mRNA–Lipid Nanoparticles Is a Promising Approach for the Development of Liver-Targeted Anti-Inflammatory Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011254

Vancouver

Rivero Berti I, Gambaro RC, Limeres MJ, Huck-Iriart C, Svensson M, Fraude-El Ghazi S, et al. Encapsulation of Dexamethasone into mRNA–Lipid Nanoparticles Is a Promising Approach for the Development of Liver-Targeted Anti-Inflammatory Therapies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011254

BibTeX
@article{RiveroBerti2024,
  author = {Rivero Berti, Ignacio and Gambaro, Rocío Celeste and Limeres, María José and Huck-Iriart, Cristián and Svensson, Malin and Fraude-El Ghazi, Silvia and Pretsch, Leah and Si, Shutian and Lieberwirth, Ingo and Landfester, Katharina and Cacicedo, Maximiliano Luis and Islan, Germán Abel and Gehring, Stephan},
  title = {Encapsulation of Dexamethasone into mRNA–Lipid Nanoparticles Is a Promising Approach for the Development of Liver-Targeted Anti-Inflammatory Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252011254}
}
Kostenlos starten →